Modulight: Sand in the gears of projects
Modulight's Q3 net revenue (0.4 MEUR) was the weakest in the company's stock market history. Due to the low revenue level, EBIT was also heavily negative at EUR -3.1 million. Our forecasts for the coming years are based on the company's reported future commercialization, for which the report did not provide significant additional visibility. We are therefore keeping our forecasts for the coming years virtually unchanged, although we made cuts for the rest of 2023. Despite the fall in the share price, the risk level of the stock is on an upward trend due to heavier-than-expected losses.
Login required
This content is only available for logged in users
Modulight
Modulight operates in the technology industry. The company designs, markets, and produces biomedical laser products used in oncology, genetics, and ophthalmology. The customers primarily consist of hospitals and corporate customers operating in medical technology. In addition to the main business, various value-added services are also offered. Their main market is the US.
Read more on company pageKey Estimate Figures20.10.2023
2022 | 23e | 24e | |
---|---|---|---|
Revenue | 4.6 | 4.5 | 8.4 |
growth-% | -49.30 % | -2.02 % | 85.93 % |
EBIT (adj.) | -7.8 | -9.1 | -3.2 |
EBIT-% (adj.) | -169.49 % | -201.32 % | -37.93 % |
EPS (adj.) | -0.20 | -0.20 | -0.07 |
Dividend | 0.00 | 0.00 | 0.00 |
Dividend % | |||
P/E (adj.) | - | - | - |
EV/EBITDA | - | - | - |